Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 4, 2000, Pages 1025-1032

  Pajonk, Frank ^a   Pajonk, Katja ^a   McBride, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

26s Proteasome; Dexamethasone; Hodgkin s disease; MG 132; NF B

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL TYPE; CLONOGENIC ASSAY; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN CELL; IMMUNOBLOTTING; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOSENSITIZATION; REED STERNBERG CELL;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HODGKIN DISEASE; HUMANS; LEUPEPTINS; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIATION TOLERANCE; RADIOBIOLOGY; TUMOR CELLS, CULTURED;

EID: 0034237661     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00516-2     Document Type: Article

References (41)

1. Aviles A., Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Clin Lab Haematol. 20:1998;95-99.
2. Liao Z., Ha C.S., Fuller L.M., et al. Subdiaphragmatic stage I & II Hodgkin's disease Long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys. 41:1998;1047-1056.
3. Gobbi P.G., Pieresca C., Ghirardelli M.L., et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood. 91:1998;2704-2712.
4. Specht L., Gray R.G., Clarke M.J., et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease A meta-analysis of 23 randomized trials involving 3, 888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 16:1998;830-843.
5. Glick J.H., Young M.L., Harrington D., et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival The 8-year results of the intergroup trial. J Clin Oncol. 16:1998;19-26.
6. Josting A., Kàtay I., Rueffer U., et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 9:1998;289-295.
7. Sweetenham J.W., Taghipour G., Milligan D., et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy Results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 20:1997;745-752.
8. Bonfante V., Santoro A., Viviani S., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [see comments]. J Clin Oncol. 15:1997;528-534.
9. Marafioti T., Hummel M., Anagnostopoulos I., et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells [see comments]. N Engl J Med. 337:1997;453-458.
10. Ohno T., Stribley J.A., Wu G., et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease [see comments]. N Engl J Med. 337:1997;459-465.
11. Schwartz R.S. Hodgkin's disease - time for a change [editorial; comment]. N Engl J Med. 337:1997;495-496.
12. Bargou R.C., Emmerich F., Krappmann D., et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 100:1997;2961-2969.
13. Wang C.Y., Mayo M.W., Korneluk R.G., et al. NF-kappaB antiapoptosis Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
14. Wu M.X., Ao Z., Prasad K.V., et al. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 281:1998;998-1001.
15. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments]. Science. 274:1996;782-784.
16. Baeuerle P.A., Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell. 53:1988;211-217.
17. Baeuerle P.A., Baltimore D. NF-kappa B Ten years after. Cell. 87:1996;13-20.
18. Wood K.M., Roff M., Hay R.T. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene. 16:1998;2131-2139.
19. Bargou R.C., Mapara M.Y., Zugck C., et al. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med. 177:1993;1257-1268.
20. Glas R., Bogyo M., McMaster J.S., et al. A proteolytic system that compensates for loss of proteasome function. Nature. 392:1998;618-622.
21. Iimuro Y., Nishiura T., Hellerbrand C., et al. NFkappaB prevents apoptosis and liver dysfunction during liver regeneration [published erratum appears in J Clin Invest1998;101:1541]. J Clin Invest. 101:1998;802-811.
22. Bargou R.C., Leng C., Krappmann D., et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 87:1996;4340-4347.
23. Auphan N., DiDonato J.A., Rosette C., et al. Immunosuppression by glucocorticoids Inhibition of NF-kappa B activity through induction of I kappa B synthesis [see comments]. Science. 270:1995;286-290.
24. Scheinman R.I., Cogswell P.C., Lofquist A.K., et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids [see comments]. Science. 270:1995;283-286.
25. Pajonk F., Pajonk K., McBride W.H. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells [In Process Citation]. J Natl Cancer Inst. 91:1999;1956-1960.
26. Gruss H.J., Ulrich D., Braddy S., et al. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol. 25:1995;2083-2089.
27. Metkar S.S., Naresh K.N., Redkar A.A., et al. CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line. Cancer Immunol Immunother. 47:1998;104-112.
28. Gruss H.J., Hirschstein D., Wright B., et al. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood. 84:1994;2305-2314.
29. Herrmann J.L., Briones F. Jr, Brisbay S., et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 17:1998;2889-2899.
30. Drexler H.C. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA. 94:1997;855-860.
31. Shinohara K., Tomioka M., Nakano H., et al. Apoptosis induction resulting from proteasome inhibition. Biochem J. 317:1996;385-388.
32. Waterhouse N.J., Finucane D.M., Green D.R., et al. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ. 5:1998;1051-1061.
33. Debiasi R.L., Squier M.K., Pike B., et al. Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors. J Virol. 73:1999;695-701.
34. Squier M.K., Miller A.C., Malkinson A.M., et al. Calpain activation in apoptosis. J Cell Physiol. 159:1994;229-237.
35. Rock K.L., Gramm C., Rothstein L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 78:1994;761-771.
36. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13-21.
37. Lee D.H., Goldberg A.L. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem. 271:1996;27280-27284.
38. Wu L.W., Reid S., Ritchie A., et al. The proteasome regulates caspase-dependent and caspase-independent protease cascades during apoptosis of MO7e hematopoietic progenitor cells. Blood Cell Mol Dis. 25:1999;20-29.
39. Jeggo P.A. Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res. 150:1998;S80-S91.
40. Rutz H.P., Mariotta M., von Knebel Doeberitz M., et al. Dexamethasone-induced radioresistance occurring independent of human papilloma virus gene expression in cervical carcinoma cells. Strahlenther Onkol. 174:1998;71-74.
41. Mariotta M., Perewusnyk G., Koechli O.R., et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol. 175:1999;392-396.